McVary Kevin T, Chughtai Bilal, Miller Larry E, Bhattacharyya Samir K, Dornbier Ryan A, Elterman Dean S
Center for Male Health, Department of Urology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA.
Department of Urology, Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA.
Med Devices (Auckl). 2021 Feb 22;14:59-64. doi: 10.2147/MDER.S265237. eCollection 2021.
Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are highly prevalent in older men. The long-term clinical utility of lifestyle modification and oral medications for LUTS is limited. There is a great clinical need for safe, effective, and durable BPH therapies for men who unsuccessfully attempt conservative measures. Enthusiasm for transurethral resection of the prostate has declined due to surgical risk, high rates of postoperative sexual dysfunction, and the perceived invasive nature therein. Consequently, interest has grown in developing minimally invasive surgical treatments (MISTs) that are efficacious but with a more favorable risk profile in order to better align with patient preferences. This review evaluates currently available MISTs for BPH. Further, we critically examine a "Leave Nothing Behind" philosophy in MIST for BPH since implantation of permanent metallic devices may be associated with increased long-term failure rates.
良性前列腺增生(BPH)继发的下尿路症状(LUTS)在老年男性中非常普遍。生活方式改变和口服药物治疗LUTS的长期临床效用有限。对于尝试保守治疗失败的男性,迫切需要安全、有效且持久的BPH治疗方法。由于手术风险、术后性功能障碍发生率高以及人们认为其具有侵入性,经尿道前列腺切除术的热情有所下降。因此,开发有效但风险特征更有利的微创外科治疗(MIST)的兴趣日益浓厚,以便更好地符合患者的偏好。本综述评估了目前可用的BPH的MIST。此外,我们严格审视了BPH的MIST中的“不留任何东西”理念,因为植入永久性金属装置可能与长期失败率增加有关。